Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

Novo Nordisk and GSK plc announced licensing deals with smaller biotechs. The FDA granted approval to Merck's drug, Welireg, ...

Septerna’s stock jumped 69% in premarket trading after the deal was announced. Novo Nordisk’s stock rose 1.2% in European trading.

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO ...

Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry varying levels of risk.

Right now, leading weight-loss drugs must be injected into the body. Pill versions could make the drugs more convenient for patients and easier to ship and store. HealthDay News — Danish ...

Braskem is considering expanding its ethylene cracker and polyethylene complex in the Brazilian state of Rio de Janeiro by 220,000 metric tons per year. During a call with analysts, company officials ...

A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity.